Jefferies Financial Group Inc. Invests $890,000 in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Jefferies Financial Group Inc. acquired a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 24,600 shares of the specialty pharmaceutical company's stock, valued at approximately $890,000.

Several other hedge funds also recently made changes to their positions in the business. Smartleaf Asset Management LLC grew its position in Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock worth $47,000 after buying an additional 870 shares during the last quarter. Mark Sheptoff Financial Planning LLC bought a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth $52,000. Headlands Technologies LLC grew its holdings in shares of Supernus Pharmaceuticals by 203.0% in the 4th quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company's stock worth $55,000 after acquiring an additional 1,015 shares during the last quarter. Newbridge Financial Services Group Inc. acquired a new position in shares of Supernus Pharmaceuticals in the 4th quarter worth $72,000. Finally, Venturi Wealth Management LLC acquired a new stake in shares of Supernus Pharmaceuticals during the fourth quarter worth $92,000.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on SUPN. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th. StockNews.com upgraded Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, May 16th.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN traded down $0.11 on Wednesday, hitting $33.10. 74,966 shares of the stock were exchanged, compared to its average volume of 487,286. The company's 50-day moving average price is $31.96 and its two-hundred day moving average price is $34.82. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of 30.83 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $40.28.

Insider Transactions at Supernus Pharmaceuticals

In other news, SVP Jonathan Rubin sold 927 shares of the stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares of the company's stock, valued at $307,444.95. This represents a 10.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.80% of the stock is currently owned by insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.